Quong Hop & Co. of South San Francisco, California is expanding their recall of tofu to include more products due to finding Listeria monocytogenes in three of twenty nine products during the Company’s sampling and in the three swabs in the manufacturing plant.
During Domestic Violence Awareness Month in October, The American College of Obstetricians and Gynecologists (ACOG) calls attention to the 2 million women in the US who are physically or sexually assaulted by an intimate partner each year. Domestic, or intimate partner, violence is an ongoing public health problem that accounts for 22% of all violent crimes against women.
Researchers in California are reporting development of a fast, inexpensive test suitable for home use that could help millions of people avoid those ‘out of the blue’ headaches that may follow consumption of certain red wines, cheese, chocolate, and other aged or fermented foods.
US health officials reported that an amoeba that typically lives in lakes and enters the body through the nose and attacks the brain has been linked to six deaths in the United States this year.
The U.S. Food and Drug Administration approved Afluria, an additional seasonal influenza vaccine for the immunization of people ages 18 and older. Afluria is intended to protect adults from influenza type A and type B flu viruses. Influenza is a contagious respiratory illness that can cause annual epidemics.
The Illinois Department of Public Health is reporting 14 additional human cases of West Nile virus including a Gallatin County woman in her 80’s who died on September_12. The woman is reported to have become ill in early September.
Quong Hop & Co. of South San Francisco, California is expanding their recall of tofu to include the following products in the following sizes and code dates: – All varieties and sizes of SOY DELI TOFU coded DEC 17 2007
The Canadian Food Inspection Agency (CFIA) and Niru Enterprises Inc. are warning the public not to consume Niru brand Coriander Powder because the product may be contaminated with Salmonella.
New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo (HR 0.55; 80 percent CI 0.41, 0.73).
The Hong Kong Department of Health advised consumers not to use Deguozhanjiang because it contains sildenafil and tadalafil, prescription drugs used for the treatment of erectile dysfunction that should only be taken under the guidance of a health professional.